Search Results
Jun 08, 2026, 11:54 ET Universal Music Group N.V. Reports Weekly Transactions under its €500 Million Share Buyback Program
press release is issued in connection with the disclosure and reporting obligations set out in Regulation (EU) No 596/2014 (the Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (each as amended).About Universal Music GroupAt Universal Music Group, we exist
More news about: Universal Music Group N.V.
Jun 08, 2026, 10:50 ET 테라바디, 첫 번째 체온 조절 퍼포먼스 기기 크라이오썸™ 팜 출시… 스포츠 최대 무대에서 열 관리를 위한 과학적인 팜 쿨링 기술 선보여
Therabody.com에서 권장 소비자 가격 399.99달러로 구매할 수 있으며, EU, 영국, 호주, 캐나다에서의 국제 출시는 2026년 가을에 이루어질 예정이다.테라바디 소개테라바디®(Therabody®)는 모든 사람이 더 좋은 상태를 느끼고, 더 잘 움직일 수 있도록 만들겠다는 사명을 가진 글로벌 웰니스 기술
More news about: Therabody
Jun 08, 2026, 10:47 ET Kết nối mọi khách hàng, mọi thiết bị, mọi công trường: XCMG CONNECT tái định hình hệ sinh thái dịch vụ công nghiệp
multimedia:https://www.prnewswire.com/vn/news-releases/u006Bu1EBFu0074u002Du006Eu1ED1u0069u002Du006Du1ECDu0069u002Du006Bu0068u0061u0063u0068u002Du0068u0061u006Eu0067u002Cu002Du006Du1ECDu0069u002D-302794098.htmlSOURCE
More news about: XCMG
Jun 08, 2026, 10:01 ET Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
struggling for growth while government debt continues to climb. Governments and the EU need to take a closer look at the role residency and citizenship by investment can play in attracting productive wealth into their economies. Our analysis
More news about: La Vida Europe Ltd
Jun 08, 2026, 10:01 ET Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight
market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
More news about: DelveInsight Business Research, LLP
Jun 08, 2026, 10:01 ET 2026 Protein Market Report: Whey Supply Crisis, FMCG-Led Growth Surge, and Ingredient Import Disruptions Reshape the $133 Billion Industry
(GMO concerns in Europe) nor pea (already being commoditised). Insect protein — particularly black soldier fly — is gaining regulatory traction in the EU and Asian markets for aquafeed reformulation, with human-food applications following at a slower pace dictated by consumer acceptance curves. The commercial
More news about: Market Decipher
Jun 08, 2026, 09:25 ET Bitmine Immersion Technologies (BMNR) Công Bố Nắm Giữ Tới 5,54 Triệu Token ETH và Tổng Cộng 9,6 Tỷ USD Tiền Mã Hóa và Tiền Mặt
multimedia:https://www.prnewswire.com/vn/news-releases/u0062u0069u0074u006Du0069u006Eu0065u002Du0069u006Du006Du0065u0072u0073u0069u006Fu006Eu002Du0074u0065u0063u0068u006Eu006Fu006Cu006Fu0067u0069-302794013.htmlSOURCE
More news about: Bitmine Immersion Technologies, Inc.
Jun 08, 2026, 09:00 ET Mullen Coughlin UK Welcomes Experienced Attorney George Chaisty as Senior Partner in London
or inadvertent network intrusions. He has an adept understanding of international data protection and privacy laws and regulations, including the UK/EU General Data Protection Regulation (GDPR). Throughout his career, George completed legal secondments at two (2) global insurance carriers, shaping
More news about: Mullen Coughlin LLC
Jun 08, 2026, 09:00 ET Mullen Coughlin UK Welcomes Experienced Attorney George Chaisty as Senior Partner in London
or inadvertent network intrusions. He has an adept understanding of international data protection and privacy laws and regulations, including the UK/EU General Data Protection Regulation (GDPR). Throughout his career, George completed legal secondments at two (2) global insurance carriers, shaping
More news about: Mullen Coughlin LLC
Jun 08, 2026, 09:00 ET Agent Governance Platform from Ares® Networks Now Available in the Microsoft Marketplace
what it actually did, and that governance policies were enforced at the moment of every interaction. This supports Caremark board oversight obligations, EU AI Act conformity requirements, and SEC disclosure accuracy.Governance is invisible to end users, administered through familiar Microsoft Entra
More news about: Ares® Networks
Jun 08, 2026, 08:50 ET Therabody、初の体温調節パフォーマンスデバイス「CryoTherm™ Palm」を発表し、科学的裏付けのある手のひら冷却でスポーツの大舞台における暑さ対策をサポート
Palmは米国運輸保安庁（TSA）の基準に準拠しており、米国ではクラス2免除医療機器、カナダではクラス2医療機器として登録されています。本製品は、米国ではTherabody.comにて希望小売価格399.99ドルで現在購入可能であり、EU、英国、オーストラリア、およびカナダでの販売は2026年秋に予定されています。
More news about: Therabody
Jun 08, 2026, 08:50 ET Xinhua Silk Road: 포시도니아 차이나 나이트, 국제 해양 교류 및 협력을 위한 고위급 플랫폼 제공
multimedia:https://www.prnewswire.com/kr/news-releases/u0078u0069u006Eu0068u0075u0061u002Du0073u0069u006Cu006Bu002Du0072u006Fu0061u0064u003Au002DuD3ECuC2DCuB3C4uB2C8uC544u002DuCC28uC774uB098u002D-302793984.htmlSOURCE
More news about: Xinhua Silk Road
Jun 08, 2026, 08:30 ET How To Strengthen Launch Strategies With Medical-Commercial Collaboration, Upcoming Webinar Hosted by Xtalks
Amplity, for the live webinar on Thursday, June 25, 2026, at 1pm EDT (7pm CEST/EU-Central).For more information, or to register for this event, visit
More news about: Xtalks
Jun 08, 2026, 08:30 ET Eco Wave Power Explores AI-Powered Wave Energy Infrastructure and WaveGPT Development with Florida Atlantic University and University of Michigan
Company has received international recognition and support from organizations including the European Union Regional Development Fund, Innovate UK, and the EU Horizon 2020 program, and was honored with the United Nations Global Climate Action Award.Eco Wave Power's American Depositary Shares (ADSs) are
More news about: Eco Wave Power Global AB (publ)
Jun 08, 2026, 08:29 ET Bybit EU umacnia swoją pozycję w Europie w kontekście nadchodzącego zakończenia okresu przejściowego przewidzianego rozporządzeniem MiCAR
cyfrowych.#BybitEU | #NewFinancialPlatformBybit EUBybit EU GmbH jest austriackim dostawcą usług związanych z kryptoaktywami (CASP) prowadzącym działalność zgodnie z rozporządzeniem w sprawie rynków kryptoaktywów (MiCAR). Bybit EU świadczy usługi na rzecz klientów z Europejskiego Obszaru
More news about: Bybit
Jun 08, 2026, 08:10 ET Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
needs.Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan's device during H2 2026 in Europe with an initial focus on Germany, Austria
More news about: Galmed Pharmaceuticals Ltd.
Jun 08, 2026, 08:05 ET THERABODY LAUNCHES CRYOTHERM™ PALM, ITS FIRST THERMOREGULATION PERFORMANCE DEVICE, BRINGING SCIENCE-BACKED PALM COOLING TO MANAGE HEAT ON SPORT'S BIGGEST STAGE
Therabody.com, with international availability in the EU, UK, Australia, and Canada coming fall 2026.ABOUT THERABODYTherabody® is the global wellness technology leader with a mission to
More news about: Therabody
Jun 08, 2026, 08:05 ET THERABODY LAUNCHES CRYOTHERM™ PALM, ITS FIRST THERMOREGULATION PERFORMANCE DEVICE, BRINGING SCIENCE-BACKED PALM COOLING TO MANAGE HEAT ON SPORT'S BIGGEST STAGE
Therabody.com, with international availability in the EU, UK, Australia, and Canada coming fall 2026.ABOUT THERABODYTherabody® is the global wellness technology leader with a mission to
More news about: Therabody
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
etentamig (ABBV-383), and approved therapies, EPKINLY® (epcoritamab-bysp) (TEPKINLY® in the EU), VENCLEXTA® (venetoclax) (VENCLYXTO® in the EU) and DECNUPAZ™ (pivekimab sunirine-pvzy). "The compelling data we are presenting at EHA reflect AbbVie's robust
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
etentamig (ABBV-383), and approved therapies, EPKINLY® (epcoritamab-bysp) (TEPKINLY® in the EU), VENCLEXTA® (venetoclax) (VENCLYXTO® in the EU) and DECNUPAZ™ (pivekimab sunirine-pvzy). "The compelling data we are presenting at EHA reflect AbbVie's robust
More news about: AbbVie
Jun 08, 2026, 08:00 ET Reco Expands Executive Team and Global Footprint to Accelerate Leadership in Enterprise AI Agent Security
and the identity risk it introduces are advancing rapidly.The company has also placed a team on the ground in the United Kingdom and Ireland. EU AI Act enforcement timelines are creating board-level urgency for AI agent governance, and European enterprise demand has grown steadily alongside U.S.
More news about: Reco
Jun 08, 2026, 07:34 ET Inside information: Betolar has been granted €2.1 million in funding under the EU LIFE programme for the MINERVA project
reduction of mining waste and environmental risks.The total estimated cost of the MINERVA project is approximately €8.8 million, of which the EU LIFE programme's share is approximately €5.3 million. Betolar's share of the total costs is €3.4 million, of which €2.1 million is funding. The estimated
More news about: Betolar Oyj
Jun 08, 2026, 05:00 ET Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
portfolio includes late and early-stage programs. CAMCEVI 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and was launched in the U.S. in April 2022. Additionally, CAMCEVI ETM was approved by the U.S. FDA on August 25, 2025. Foresee
More news about: Foresee Pharmaceuticals Co., Ltd.
Jun 08, 2026, 03:56 ET Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10% of patients with primary brain tumors are children. The prognosis for individuals with glioblastoma is very poor, as approximately
More news about: Curasight
Jun 08, 2026, 03:53 ET Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
diagnosed with primary brain tumors, and more than 30,000 patients are diagnosed annually with the most aggressive form, glioblastoma, in the US and EU. Approximately 10% of patients with primary brain tumors are children. The prognosis for individuals with glioblastoma is very poor, as approximately
More news about: Curasight